Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
Janoshik
Batch ELOR-CA-26G-10
Selective Amylin Receptor Agonist
Also known as Elaronitide, Elorantide, LY3841136
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
Note that no compound named "elaronitide" appears in PubMed, PubChem, or the INN register. The vial artwork spelling appears to be in error.
Eloralintide is a selective agonist of the AMY1 amylin receptor, engineered with a fatty-diacid conjugate that supports albumin binding and an extended half-life. Research has characterized its selectivity for AMY1R over the calcitonin receptor and other amylin receptor subtypes.
Clinical research has evaluated the compound across phase 1 and phase 2 programmes, examining amylin-pathway pharmacology and body-weight endpoints under controlled conditions.
Eloralintide was developed as part of research into amylin-pathway agonists as an alternative to incretin-based mechanisms for metabolic regulation. Discovery and early characterization work described its receptor selectivity and long-acting design.
Subsequent phase 1 and phase 2 studies characterized its pharmacological profile in obesity research populations.
Research into eloralintide focuses on selective amylin receptor activation and its metabolic consequences. Frameworks evaluate receptor-subtype selectivity, pharmacokinetics of the long-acting design, and body-weight endpoints under controlled clinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of eloralintide. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
PubMedEloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
PubMedEloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
PubMedLong-acting amylin-related peptides as therapies for obesity and type 2 diabetes
PubMedRelated
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$50.00
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
$50.00
$60.00
Synthetic thymosin beta analog studied for cellular migration, actin regulation, and repair signaling pathways
From$60.00
Tripeptide studied for anti-inflammatory signaling, immune modulation, and cellular response pathways
From$49.99
